Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRTS NASDAQ:JNCE NASDAQ:MGTX NASDAQ:OYST NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTSGritstone bio$0.35$0.03▼$3.17$3.50M0.497.01 million shs61.02 million shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsMGTXMeiraGTx$7.32-0.1%$7.94$3.94▼$8.98$588.87M1.29508,232 shs245,709 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsSLDBSolid Biosciences$5.41-1.5%$5.96$2.41▼$8.10$421.28M2.541.80 million shs711,264 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTSGritstone bio0.00%0.00%0.00%0.00%-94.15%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-3.68%-1.87%-10.28%+15.80%+72.47%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTSGritstone bio$0.35$0.03▼$3.17$3.50M0.497.01 million shs61.02 million shsJNCEJounce Therapeutics$1.88$1.89$0.58▼$5.87$98.94M0.752.46 million shs169,314 shsMGTXMeiraGTx$7.32-0.1%$7.94$3.94▼$8.98$588.87M1.29508,232 shs245,709 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsSLDBSolid Biosciences$5.41-1.5%$5.96$2.41▼$8.10$421.28M2.541.80 million shs711,264 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTSGritstone bio0.00%0.00%0.00%0.00%-94.15%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-3.68%-1.87%-10.28%+15.80%+72.47%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTSGritstone bio 2.50Moderate Buy$0.75∞ UpsideJNCEJounce Therapeutics 0.00N/AN/AN/AMGTXMeiraGTx 3.00Buy$24.00227.65% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/ASLDBSolid Biosciences 3.09Buy$15.00177.01% UpsideCurrent Analyst Ratings BreakdownLatest GRTS, JNCE, OYST, SLDB, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTSGritstone bio$496K0.00N/AN/A$0.54 per share0.00JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53MGTXMeiraGTx$37.92M15.54N/AN/A$0.87 per share8.42OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94SLDBSolid Biosciences$8.09M52.12N/AN/A$3.43 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/AJNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/AMGTXMeiraGTx-$147.79M-$2.04N/A19.28N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ASLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest GRTS, JNCE, OYST, SLDB, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRTSGritstone bioN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTSGritstone bio1.832.542.54JNCEJounce TherapeuticsN/A8.378.37MGTXMeiraGTx26.290.880.88OYSTOyster Point Pharma8.493.353.11SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTSGritstone bio48.46%JNCEJounce Therapeutics80.66%MGTXMeiraGTx67.48%OYSTOyster Point Pharma96.70%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipGRTSGritstone bio4.61%JNCEJounce Therapeutics6.92%MGTXMeiraGTx7.50%OYSTOyster Point Pharma17.90%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRTSGritstone bio190108.57 million111.84 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableSLDBSolid Biosciences10077.87 million67.26 millionOptionableGRTS, JNCE, OYST, SLDB, and MGTX HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Solid Biosciences (NASDAQ:SLDB) to SellSeptember 15 at 2:43 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Lowered by Wall Street ZenSeptember 15 at 2:55 AM | marketbeat.comSiren L.L.C. Has $27.44 Million Holdings in Solid Biosciences Inc. $SLDBSeptember 13 at 3:12 AM | marketbeat.comSolid Biosciences Inc. $SLDB Shares Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Stock Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Has $204,000 Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comBrokerages Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.00September 7, 2025 | americanbankingnews.comEcoR1 Capital LLC Purchases New Stake in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comJump Financial LLC Acquires New Position in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comSolid Biosciences Inc. $SLDB is Bain Capital Life Sciences Investors LLC's 7th Largest PositionSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stake in Solid Biosciences Inc. $SLDBSeptember 5, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRedmile Group LLC Has $7.47 Million Stock Position in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 1,096,442 Shares of Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comBirchview Capital LP Makes New Investment in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Invests $6.08 Million in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDBSeptember 3, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comApis Capital Advisors LLC Purchases Shares of 110,000 Solid Biosciences Inc. $SLDBSeptember 2, 2025 | marketbeat.comSolid Biosciences to Participate at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comResolute Capital Asset Partners LLC Makes New $555,000 Investment in Solid Biosciences Inc. $SLDBAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTS, JNCE, OYST, SLDB, and MGTX Company DescriptionsGritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Jounce Therapeutics NASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.MeiraGTx NASDAQ:MGTX$7.32 -0.01 (-0.14%) Closing price 04:00 PM EasternExtended Trading$7.31 -0.01 (-0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Solid Biosciences NASDAQ:SLDB$5.41 -0.08 (-1.46%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.08 (+1.39%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
